NCT07326137Recruiting
A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain
A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade in Patients With Advanced Biliopancreatic Malignancies and Cancer-Related Pain
Source: ClinicalTrials.gov · Last updated 11 Feb 2026
Brief summary (registry, in English)
This study is for patients with advanced bile duct or pancreatic cancer who are experiencing pain from their disease. The purpose of this research is to learn about the effects of combining a standard pain relief treatment (Celiac Plexus Block) with standard first-line cancer drugs. Patients in this study will receive the Celiac Plexus Block procedure, which is intended to reduce pain, and will then begin their standard cancer medication regimen. Researchers will observe and compare how well this combined approach works to control pain and the cancer itself, and will monitor for any side effects. Participation in this study involves being followed by the research team for up to 2 years to track health outcomes. The goal is to see if starting cancer treatment together with this specialized pain management technique is more helpful for patients compared to what is already known about the standard treatments alone.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 103 (estimated)
- First submitted
- 25 Dec 2025
- Start date
- 26 Dec 2025
- Primary completion date
- 26 Jun 2028
- Lead sponsor
- Tongji Hospital
- NCT number
- NCT07326137
What you commit to
- Study type: Observational
- Planned participants: 103
- From 26 Dec 2025 to the primary completion date, 26 Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous history of celiac plexus neurolysis or ablation.
Other illness
- Contraindications to celiac plexus block (e.g., local infection, anatomical variation).
- Any other condition that, in the investigator's judgment, would preclude safe participation in the study.
Lab values
- Coagulation disorders (INR \> 1.5, platelet count \< 50 × 10⁹/L).
- Severe cardiac, hepatic, or renal insufficiency (Child-Pugh Class C, estimated glomerular filtration rate (eGFR) \< 30 mL/min, NYHA Class III-IV heart failure).
Who the study is looking for
- Histologically confirmed advanced biliopancreatic malignancy (including biliary tract cancer or pancreatic cancer).
- Cancer-related pain: Baseline Numeric Rating Scale (NRS) pain score ≥ 4 points for over 1 week, with plans to receive celiac plexus neurolysis (CPN).
- Scheduled to receive a first-line systemic treatment regimen (e.g., PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy/targeted therapy).
- ECOG Performance Status of 0-2 and an estimated life expectancy of ≥ 3 months.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tongji Hospital Coordinator of this site? Confirm its status | Wuhan | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.